Tixagevimab/AZD8895 represents a distinct treatment method utilizing two monoclonal antibodies. Specifically, these medications function by selectively binding to the S1 region of the SARS-CoV-2 agent, preventing its https://bookmarks-hit.com/story101042/tixagevimab-azd8895-a-deep-examination-into-its-mechanism-of-operation